Monitor upcoming regulatory milestones, including completion of the BLA submission in H2 2026 and potential FDA approval timeline. Evaluate competitive positioning against existing chronic HAE therapies and assess commercial readiness indicators such as payer engagement and field team scaling.
Price Chart
Executive Summary
Intellia Therapeutics announced positive Phase 3 topline data for its investigational CRISPR-based therapy lonvo-z in hereditary angioedema (HAE), demonstrating an 87% attack reduction and 62% of patients becoming attack-free. The company also initiated a rolling biologics license application (BLA) with the FDA, targeting a potential U.S. launch in the first half of 2027.
Key Facts
- HAELO Phase 3 trial met primary and all key secondary endpoints with high statistical significance (p<0.0001)
- Lonvo-z reduced HAE attacks by 87% vs. placebo (0.26 vs. 2.10 mean monthly attack rate)
- 62% of patients in the lonvo-z arm were entirely attack-free and therapy-free during the six-month efficacy period
- All patients in the lonvo-z arm experienced attack rate reduction from baseline
- Favorable safety profile with no serious adverse events in the lonvo-z arm; most common events were mild-to-moderate infusion-related reactions
- Rolling BLA submission initiated with the FDA; full submission expected in second half of 2026
- Potential U.S. launch targeted for first half of 2027 if approved
Financial Impact
Significant potential revenue upside if approved, with lonvo-z positioned as a one-time curative therapy in a market with high unmet need and substantial treatment costs
Risk Factors
- Regulatory approval is not guaranteed despite positive Phase 3 data
- Commercial execution risk in launching a novel gene therapy, including pricing, reimbursement, and market adoption
- Potential safety signals in longer-term follow-up data
- Competition from other HAE therapies in development
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-179401 |
| Document: d138980d8k.htm | 0001193125-26-179401 |
| Document: d138980dex991.htm | 0001193125-26-179401 |
| Document: 0001193125-26-179401-index-headers.html | 0001193125-26-179401 |
| Document: 0001193125-26-179401-index.html | 0001193125-26-179401 |
| Document: 0001193125-26-179401.txt | 0001193125-26-179401 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 2, 2026 23d ago | Press Release | $12.75 $12.58 | ▼ −1.33% | ▼ −1.76% | $11.23 (−11.92%) |
Sep 8, 2026 6w ago | 8-K | $12.21 $11.60 | ▼ −5.00% | ▼ −4.66% | $11.23 (−8.03%) |
Aug 6, 2026 11w ago | 8-K | $11.24 $11.83 | ▲ +5.25% | ▲ +4.04% | $11.23 (−0.09%) |
Jun 15, 2026 19w ago | 8-K | $14.92 $15.75 | ▲ +5.56% | ▲ +6.95% | $11.23 (−24.73%) |
Jun 13, 2026 19w ago | Press Release | $14.92 $15.75 | ▲ +5.56% | ▲ +6.95% | $11.23 (−24.73%) |
Jun 1, 2026 21w ago | Press Release | $13.73 $13.54 | ▼ −1.38% | ▲ +1.37% | $11.23 (−18.21%) |
May 11, 2026 24w ago | 8-K | $14.42 $12.69 | ▼ −12.00% | ▼ −11.91% | $11.23 (−22.12%) |
Apr 27, 2026 25w ago | Press Release | $13.20 $13.87 | ▼ −5.08% | ▼ −3.38% | $11.23 (+14.92%) |
Apr 27, 2026 26w ago | 8-K | $13.04 $13.87 | ▲ +6.37% | ▲ +5.96% | $11.23 (−13.88%) |
Apr 3, 2026 29w ago | Press Release | $13.30 $14.26 | ▲ +7.22% | ▲ +3.08% | $11.23 (−15.56%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers